DMBA and TPA Induced Two-Stage Skin Carcinoma Model Service

The two-stage skin carcinoma model, built on a single initiating dose of DMBA followed by repeated TPA promotion, is the foundational paradigm that first separated tumor initiation from tumor promotion and continues to anchor stage-specific cancer research. Alfa Cytology runs this venerable platform to modern standards, coordinating dorsal skin preparation, topical dosing calendars, weekly tumor palpation, and full histological staging of papillomas and squamous cell carcinomas within one continuous, audit-ready workflow.

Overview of DMBA and TPA Induced Two-Stage Skin Carcinoma Model

Few experimental systems have shaped cancer biology as profoundly as the two-stage mouse skin model, which for more than sixty years has converted a simple pair of chemicals into a complete map of epithelial tumorigenesis. In the initiating step, a single subcarcinogenic application of the polycyclic aromatic hydrocarbon 7,12-dimethylbenz[a]anthracene (DMBA) in acetone is painted onto shaved dorsal skin, where cutaneous CYP1A1 and CYP1B1 convert it to reactive metabolites that bind DNA in keratinocyte stem cells of the interfollicular epidermis and hair follicle bulge. The signature lesion is an activating mutation at codon 61 of the H-ras oncogene, an irreversible event that is invisible macroscopically and can remain dormant for up to a year until a promoter acts upon it.

Fig 1. Lineage-tracing strategy of skin stem cell compartments combined with DMBA/TPA carcinogenesis, showing tdTomato-labeled Lgr6+ and Lrig1+ upper hair follicle stem cells as the predominant origin of papillomas. (Kalniņa Z, et al., 2025)

The promoting step begins roughly two weeks later with twice-weekly applications of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), which is not meaningfully mutagenic but potently activates protein kinase C, AP-1 transcriptional programs, and inflammatory and oxidative signaling that drive sustained epidermal hyperplasia. Within this hyperplastic environment, initiated cells enjoy a selective growth advantage and expand into finger-like clonal outgrowths called papillomas, which typically appear after six to twelve weeks of promotion and yield a highly reproducible tumor burden within ten to twenty weeks. Over longer horizons, approximately 10–20% of papillomas progress to squamous cell carcinomas, and additional mutagenic insults, the basis of so-called three-stage protocols, can accelerate that conversion. Because initiation and promotion can be separated operationally and mechanistically, the model remains indispensable for chemoprevention screening, for dissecting which stage a compound inhibits, and for studying malignant progression in vivo.

Principles of DMBA and TPA Induced Two-Stage Skin Carcinoma Model Construction

Although the two-stage protocol is technically straightforward, its output is exquisitely sensitive to initiator dose, promoter schedule, strain sensitivity, and lesion classification discipline. The critical elements are tabulated below.

Our Services

With its stage-by-stage architecture, the DMBA/TPA model demands exacting calendar control, and Alfa Cytology meets that demand through written dosing schedules, blinded weekly tumor scoring, and standardized histological confirmation of every scored lesion.

Workflow of DMBA and TPA Induced Two-Stage Skin Carcinoma Model Construction

A two-stage skin study is deceptively short in setup but unforgiving in execution: a single initiation event followed by months of twice-weekly promotion and weekly tumor scoring. A standard engagement follows the sequence below.

1. Study design and strain selection: The sponsor's objectives determine the strain, typically SENCAR for sensitivity, CD-1 or ICR for robustness, or rasH2 for short timelines, along with initiator and promoter doses, group sizes, and any three-stage progression arms.
2. Animal acclimatization and randomization: Six- to eight-week-old mice undergo a minimum one-week habituation, are randomized by weight, and are assigned to individually identified cages that will support long-term topical dosing.
3. Dorsal skin preparation: The dorsal hair is clipped (and chemically depilated where required by protocol) 24–48 hours before initiation, exposing a uniform application field while preserving skin barrier integrity.
4. DMBA initiation: A single dose of DMBA in acetone is applied topically to the prepared dorsal skin under controlled conditions, and animals are returned to their cages without further manipulation until promotion begins.
5. TPA promotion phase: Beginning approximately two weeks after initiation, TPA in acetone is applied twice weekly for the duration specified by the study design, commonly 18–20 weeks, with dosing volumes and skin condition logged at every session.
6. Weekly tumor scoring: Animals are palpated once weekly by trained, blinded scorers; every palpable mass larger than 1 mm is recorded with its size and location, building the multiplicity, incidence, and latency datasets that drive analysis.
7. Intervention scheduling (therapeutic or chemoprevention arms): Test articles are administered on the sponsor-defined calendar, with anti-initiation compounds given before or with DMBA, anti-promotion compounds dosed around TPA applications, and progression-stage agents started after papilloma establishment.
8. Endpoint necropsy and histological confirmation: At the final time point, animals are euthanized, skin with lesions is excised and fixed, and all scored masses are sectioned for H&E confirmation as papilloma or squamous cell carcinoma, complemented by PCNA/Ki-67 proliferation staining and COX-2 or MMP-9 inflammatory marker analysis.

Fig 2. Two-Stage Skin Carcinoma Model Construction Workflow.

Case Study-DMBA and TPA Induced Two-Stage Skin Carcinoma Model Development

Alfa Cytology has employed the DMBA/TPA platform across preclinical programs in chemoprevention, where anti-initiation and anti-promotion mechanisms can be assigned to distinct protocol windows, as well as in malignant-progression studies built on three-stage designs. These engagements have produced rigorously scored tumor incidence, multiplicity, and latency datasets, histologically verified lesion classifications, and supporting immunohistochemistry spanning proliferation and inflammatory markers. Prospective partners may request further information on study designs and representative outputs under appropriate confidentiality arrangements.

Why Choose Alfa Cytology?

In a model where timing is biology, Alfa Cytology treats the dosing calendar as a contractual deliverable, and backs it with scoring rigor and histological verification.

• Strain portfolio spanning SENCAR, CD-1, ICR, and rasH2 to match sensitivity and timeline requirements.
• Written dosing calendars with per-session logging of volumes, dates, and skin condition for complete traceability.
• Blinded weekly palpation by trained scorers using the >1 mm papilloma convention.
• Stage-targeted intervention scheduling that cleanly separates anti-initiation from anti-promotion mechanisms.
• Optional three-stage progression arms that convert rare carcinoma conversion into a high-yield readout.
• Histological confirmation of every scored lesion by Ph.D.-level pathologists with full H&E and marker panels.

Contact Us

For a carcinogenesis platform where every stage of tumor development can be isolated, dosed, and scored, Alfa Cytology invites you to put the two-stage skin model to work. Contact us or reach out to our scientific team today, and we will assemble a stage-specific study plan and quotation aligned with your preclinical objectives.

For research use only. Not intended for any clinical use.